| 11/08/26 | 07:00:05 | 11 Aug 2026 | | Parsortix CTCs used for Brain Cancer detection | RNS |
| 03/08/26 | 07:00:09 | 3 Aug 2026 | | Parsortix CTCs used for ADC target assessment | RNS |
| 16/07/26 | 07:00:04 | 16 Jul 2026 | | Issue of Share Options | RNS |
| 15/07/26 | 07:00:04 | 15 Jul 2026 | | Q2 and First Half Year Results ended 30 June 2026 | RNS |
| 14/07/26 | 09:46:52 | 14 Jul 2026 | | Result of AGM | RNS |
| 14/07/26 | 07:00:03 | 14 Jul 2026 | | AGM Statement | RNS |
| 06/07/26 | 16:45:00 | 6 Jul 2026 | | Directorate change | RNS |
| 22/06/26 | 07:00:10 | 22 Jun 2026 | | Preliminary Results | RNS |
| 16/06/26 | 07:00:08 | 16 Jun 2026 | | Notice of Results | RNS |
| 29/05/26 | 07:00:03 | 29 May 2026 | | MSA with Global Pharmaceutical Company | RNS |
| 18/05/26 | 07:00:07 | 18 May 2026 | | Collaboration with AdventHealth for two studies | RNS |
| 11/05/26 | 07:00:10 | 11 May 2026 | | Q1 trading update and outlook for 2026 | RNS |
| 30/04/26 | 07:00:10 | 30 Apr 2026 | | Confirmation of Q1 trading update | RNS |
| 20/04/26 | 07:00:07 | 20 Apr 2026 | | Research Collaboration with The Royal Marsden | RNS |
| 16/04/26 | 17:39:48 | 16 Apr 2026 | | Board changes - Replacement | RNS |
| 13/02/26 | 07:00:06 | 13 Feb 2026 | | Aligning Regulatory Approach with Commercial Needs | RNS |
| 16/01/26 | 07:00:06 | 16 Jan 2026 | | Preliminary Fourth Quarter 2025 Financial Results | RNS |
| 12/01/26 | 07:00:07 | 12 Jan 2026 | | Board changes | RNS |
| 23/12/25 | 09:15:05 | 23 Dec 2025 | | Holding(s) in Company | RNS |
| 19/12/25 | 17:51:11 | 19 Dec 2025 | | PDMR Dealing and ESOT Share Purchase | RNS |
| 15/12/25 | 14:41:11 | 15 Dec 2025 | | Results of General Meeting and Board Changes | RNS |
| 02/12/25 | 11:11:53 | 2 Dec 2025 | | Additional Subscription | RNS |
| 01/12/25 | 17:44:06 | 1 Dec 2025 | | Result of Retail Offer | RNS |
| 25/11/25 | 17:40:08 | 25 Nov 2025 | | Update to Admission of Fundraising Shares | RNS |
| 25/11/25 | 08:00:01 | 25 Nov 2025 | | Launch of Retail Offer | RNS |
| 25/11/25 | 07:55:39 | 25 Nov 2025 | | Result of Oversubscribed Placing and Subscription | RNS |
| 24/11/25 | 18:32:00 | 24 Nov 2025 | | Proposed Placing and Subscription | RNS |
| 18/11/25 | 07:00:09 | 18 Nov 2025 | | QIAGEN Collaboration and Co-Marketing Agreement | RNS |
| 05/11/25 | 18:16:02 | 5 Nov 2025 | | Further Update on Funding | RNS |
| 05/11/25 | 07:00:12 | 5 Nov 2025 | | CelLBxHealth Presents Proof-of-Concept Study | RNS |
| 04/11/25 | 07:00:11 | 4 Nov 2025 | | Expert Consensus on CTCs; Update on Funding | RNS |
| 29/10/25 | 07:00:11 | 29 Oct 2025 | | CHANGE OF NAME | RNS |
| 16/10/25 | 07:00:09 | 16 Oct 2025 | | Appointments: Interim CEO and senior board advisor | RNS |
| 08/10/25 | 07:00:10 | 8 Oct 2025 | | Strategy Update | RNS |
| 29/09/25 | 07:00:18 | 29 Sept 2025 | | Presentation of Data on Glioblastoma | RNS |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | Board Changes | RNS |
| 09/09/25 | 07:01:00 | 9 Sept 2025 | | Interim Results | RNS |
| 09/09/25 | 07:00:17 | 9 Sept 2025 | | Change of Adviser | RNS |
| 05/09/25 | 14:58:52 | 5 Sept 2025 | | Notice of Results | RNS |
| 20/08/25 | 07:00:03 | 20 Aug 2025 | | ANGLE announces collaboration with Myriad Genetics | RNS |
| 08/07/25 | 07:00:12 | 8 Jul 2025 | | PARSORTIX ENABLES STUDY OF CANCER PROGRESSION | RNS |
| 30/06/25 | 17:50:10 | 30 Jun 2025 | | Result of 2025 Annual General Meeting | RNS |
| 17/06/25 | 07:00:12 | 17 Jun 2025 | | EACR 2025: Innovation in AR expression profiling | RNS |
| 17/06/25 | 07:00:10 | 17 Jun 2025 | | EACR 2025: Data demonstrating DNA dual analysis | RNS |
| 10/06/25 | 07:00:14 | 10 Jun 2025 | | Novel discoveries into the biology of cancer | RNS |
| 09/06/25 | 07:00:10 | 9 Jun 2025 | | POSTING OF ANNUAL REPORT AND NOTICE OF AGM | RNS |
| 06/06/25 | 07:00:12 | 6 Jun 2025 | | Board Changes | RNS |
| 28/05/25 | 07:00:05 | 28 May 2025 | | Preliminary Results | RNS |
| 23/05/25 | 07:00:09 | 23 May 2025 | | Notice of Results | RNS |
| 28/04/25 | 07:00:09 | 28 Apr 2025 | | RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME | RNS |
